Shares of ImmunoGen Inc. rocketed toward a 23-year high Thursday after the biotechnology company agreed to be acquired buy AbbVie Inc. in a cash deal valued at $10.1 billion. AbbVie said the deal ...

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.

Drug company AbbVie has agreed to buy biotech ImmunoGen for $10.1 billion in a fresh bet on one of the most promising new technologies for attacking cancer. ImmunoGen develops cancer drugs called ...

It comes shortly after AbbVie offered $10.1 billion to buy ImmunoGen and its marketed ovarian cancer drug Elahere (mirvetuximab soravtansine), and a pipeline of other antibody-drug conjugates for ...

Among some other larger deals, AbbVie acquired ImmunoGen last year ... see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked ...

AbbVie's longtime CEO, Richard Gonzalez, who held his position since the business spun off from Abbott Laboratories in 2013, ...

We recently compiled a list of the 10 Best Cancer Stocks To Buy Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other cancer stocks.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune ...

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report) and keeping the price target at ...

AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has also outperformed the sector and S&P 500 index as seen in the chart ...

Among some other larger deals, AbbVie acquired ImmunoGen last year, which added the latter’s ... You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest ...